ALLO
Allogene Therapeutics, Inc.
Latest Form 4:Sale$22KbyYoshiyama Annie (SVP, Finance) · filed Apr 23, 2026
Allogene Therapeutics, Inc. (ALLO) has 14 SEC Form 4 filings (14 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Jun 23, 2026.
The most active filer is SVP, Chief Technical Officer Beneski Benjamin Machinas with 4 filings. Insiders have net sold $556K over the trailing 6 months.
- Industry:Biotechnology
- CEO:Zachary Roberts
- Employees:152
- HQ:South San Francisco, CA, US
- IPO:2018-10-11
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$556K
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
Market Cap
$701.3M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| SVP, Finance | Sale | 9,586 | $22K | Apr 23 | SEC ↗ | |
| SVP, Chief Technical Officer | Sale | 2,867 | $7K | Apr 2 | SEC ↗ | |
| SVP, Chief Technical Officer | Sale | 4,835 | $12K | Mar 18 | SEC ↗ | |
| President and CEO | Sale | 47,763 | $118K | Mar 18 | SEC ↗ | |
| SVP, Chief Technical Officer | Sale | 7,132 | $19K | Mar 4 | SEC ↗ | |
Beneski Benjamin MachinasFirst filing | SVP, Chief Technical Officer | Sale | 7,549 | $13K | Feb 4 | SEC ↗ |
Yoshiyama AnnieFirst filing | SVP, Finance | Sale | 4,167 | $7K | Feb 4 | SEC ↗ |
| EVP of R&D | Sale | 35,700 | $63K | Feb 4 | SEC ↗ | |
Douglas Earl MartinFirst filing | SVP, General Counsel | Sale | 22,900 | $40K | Feb 4 | SEC ↗ |
Parker Geoffrey M.First filing | CHIEF FINANCIAL OFFICER | Sale | 24,001 | $42K | Feb 4 | SEC ↗ |
Chang David DFirst filing | President and CEO | Sale | 95,269 | $171K | Feb 4 | SEC ↗ |
Roberts ZacharyFirst filing | EVP of R&D | Sale | 26,269 | $41K | Jan 23 | SEC ↗ |
Related companies
Allogene Therapeutics, Inc. is in the Healthcare sector.